Pacira BioSciences, Inc. · Drugmakers

PCRX

Low riskNext report: Around Nov 5 (est.)

View price ↗

The short version

A profitable company with steady sales.

Going well

Profitable
Brings in more cash than it spends
Buying back shares: share count down 3.2% in 3 years

Money moves

Insiders sold $218K in the last 30 days, all through pre-planned sales
Institutions added 1.4% to their holdings in the quarter ending June 2026 (118 bought, 107 sold)

Facts from SEC filings, not a recommendation.

What the price means

Price as of Oct 26

$36.39-0.1% that day

Company value: $1.5B; Share price times all shares
Price vs profit (P/E): 104.0x; You pay about $104 for each $1 of yearly profit
Price vs sales: 1.9x; Company value is 1.9 times a year of sales
Cash vs value: 14%; Cash as a share of company value
Debt vs value: 26%; Debt as a share of company value

From PCRX's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.

The business over time

Last 12 quarters, from SEC filings

Sales, Jun '26

$192.4M+6.2% vs a year earlier

Sep '23Tap a barJun '26

Last 12 months: $746.2M, up 5.7% from the 12 months before. Over 5 years, sales grew about 11% a year.

What the price assumes

Your guesses, our math

Move the sliders to your own view of PCRX. Starting points are the company's recent numbers.

Sales growth+6% a yearRecently: +5.7% a yearProfit margin2%Last 12 months: 2.0%P/E at the end40xToday: 104.0x. Many steady companies trade at 12x to 25xShare count change-1% a yearBelow zero means buybacks; above zero means new shares (dilution)

Sales in 5 years$999M

Profit in 5 years$20M

Price these guesses point to$21.07-42% vs $36.39 todayAbout -10% a year, before dividends

What today's price needs: with a 2% margin and a 40x P/E, sales would have to grow about 18% a year for 5 years just to match today's price.

Simple math on your guesses, not a forecast or a price target. Real results depend on many things these sliders leave out.

Price

Price chart by TradingView.

Business quality

The checklist Warren Buffett-style investors use. Annual numbers for 2025.

2/6Weak

MissReturn on equity 15%+Earns a lot on the money owners have in the business.1.0%
MissDebt under half of equityNot relying on borrowed money.0.54x equity
MissNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.1.0%
MissProfitable every yearSteady profits, not one good year.5 of 10 years
PassFree cash flow positiveBrings in more cash than it spends to run and grow.$136.7M
PassShare count not growingNot diluting owners. Falling means buybacks.-3.2% in 3 years

Revenue: $726.4M; +3.6% vs prior year
5-year growth: +11.1%/yr; revenue, per year
Total debt: $372.2M; 0.54x equity
Current ratio: 4.54x; short-term assets / bills due

From annual reports filed with the SEC. Not in this company's SEC data, so not scored: gross margin 40%+. A checklist is a starting point for research, not a verdict.

Latest quarter

Quarter ended Jun 30, 2026

Reported Aug 4

Revenue: $192.4M; +6.2% YoY
EPS: $0.12; vs -$0.11
Op. margin: 2.2%; -2.5 pts
Gross margin: 77.0%; -0.4 pts
Free cash flow: $56.1M
Share count: -11.3%; vs a year ago

Insider rating

Last 90 days

47Mixed

Pre-planned sales of $218K (weaker signal)

50 is neutral. Buying by more insiders, top executives and bigger stakes raises it. Selling lowers it; pre-planned sales count less.

Weekly insider trend

13 weeks agoBoughtSoldThis week

Filing buzz

Last 7 days vs normal

0/ 100

This week: 0
Normal week: 1.0
vs normal: 0.0x

SEC filings of any kind. 50 means a normal week.

Institutional ownership

Steady+1.4%

Institutions added 1.4% to their holdings. 118 bought, 107 sold.

Shares held by institutions44.0M

Sep '24Jun '26

Safety check

From SEC filings

Share count growthYearly rate, last 3 years

-4.9%

Cash runwayAt last year's cash burn

Cash flow positive

Debt to equityLatest balance sheet: debt compared with what owners have

0.5x · $363.1M debt

Shares outstandingLatest reported

40M

Earnings reports

Last 12

Next reportAround Nov 5 (est.)Estimated from the same quarter last year

Results filedAug 4
Results filedApr 30
Results filedFeb 26
Results filedJan 8
Results filedNov 6, 2025

Flags and big holders

Offerings 6 months, flags 12 months, holders 90 days

5%+ holder update (active)Oct 13 · View filing ↗Activist New 5%+ holder (passive)Aug 7 · View filing ↗Big holder

Insider trades

Open-market buys and sells, last 90 days

Bought$00 insiders

Sold$218K1 insider, 1 pre-planned

Insider	Trade	Shares	Avg price	Value	Owns after	Date
Lauren RikerSenior Vice President, Finance	Sell	6K	$36.32	$218K	62K	Oct 8Filing ↗
-8.8% of their holdings Pre-planned sale (10b5-1) Filed 1 day after

"Owns after" is the insider's holding right after the trade. Pre-planned (10b5-1) sales are set up months ahead, a weaker signal.

Latest filings

Straight from SEC EDGAR

5%+ holder update (active)Oct 13 · Form SCHEDULE 13D/A ↗

SoldLauren RikerSenior Vice President, Finance

6,000 shares at $36.32 · $218K

-9% of holdings
Now owns 62,284 shares
Pre-planned sale (10b5-1)
Filed 1 day after trade
Also: Option exercise

Oct 8Form 4 ↗

SC TO-COct 8 · Form SC TO-C ↗Major agreementOct 8 · Form 8-K ↗Planned insider saleOct 8 · Form 144 ↗SC14D9COct 8 · Form SC14D9C ↗SC TO-COct 8 · Form SC TO-C ↗

SoldJonathan SloninChief Medical Officer

3,040 shares at $23.23 · $71K

-1% of holdings
Now owns 216,384 shares
Pre-planned sale (10b5-1)
Filed 1 day after trade

Aug 17Form 4 ↗

Planned insider saleAug 17 · Form 144 ↗New 5%+ holder (passive)Aug 7 · Form SCHEDULE 13G ↗Earnings resultsAug 4 · Form 8-K ↗Quarterly reportAug 4 · Form 10-Q ↗Employee stock plan registrationAug 4 · Form S-8 ↗Major agreementJun 30 · Form 8-K ↗Planned insider saleJun 12 · Form 144 ↗

Source: SEC EDGAR filings. For informational purposes. Not investment advice.

Report a problem with this page